IDEAS home Printed from https://ideas.repec.org/p/iza/izadps/dp9143.html
   My bibliography  Save this paper

Increasing Coverage of Antiretroviral Therapy and Male Medical Circumcision in HIV Hyperendemic Countries: A Cost-Benefit Analysis

Author

Listed:
  • Geldsetzer, Pascal

    (Harvard School of Public Health)

  • Bloom, David E.

    (Harvard School of Public Health)

  • Humair, Salal

    (Harvard School of Public Health)

  • Bärnighausen, Till

    (Harvard School of Public Health)

Abstract

HIV continues to cause the largest number of disability-adjusted life years of any disease in HIV hyperendemic countries (i.e., countries with an adult HIV prevalence >15%). We compare the benefits and costs of two proven biological interventions to reduce the health losses due to the HIV epidemic in hyperendemic countries from 2015 through 2030: 1) increasing ART coverage to 90% among HIV-infected adults with a CD4-cell count

Suggested Citation

  • Geldsetzer, Pascal & Bloom, David E. & Humair, Salal & Bärnighausen, Till, 2015. "Increasing Coverage of Antiretroviral Therapy and Male Medical Circumcision in HIV Hyperendemic Countries: A Cost-Benefit Analysis," IZA Discussion Papers 9143, Institute of Labor Economics (IZA).
    • Handle: RePEc:iza:izadps:dp9143
    as

    Download full text from publisher

    File URL: https://docs.iza.org/dp9143.pdf
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Caryl Feldacker & Isaac Holeman & Vernon Murenje & Sinokuthemba Xaba & Michael Korir & Bill Wambua & Batsirai Makunike-Chikwinya & Marrianne Holec & Scott Barnhart & Mufuta Tshimanga, 2020. "Usability and acceptability of a two-way texting intervention for post-operative follow-up for voluntary medical male circumcision in Zimbabwe," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-18, June.

    More about this item

    Keywords

    HIV; male medical circumcision; antiretroviral therapy; cost-benefit analysis;
    All these keywords.

    JEL classification:

    • D61 - Microeconomics - - Welfare Economics - - - Allocative Efficiency; Cost-Benefit Analysis
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:iza:izadps:dp9143. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Holger Hinte (email available below). General contact details of provider: https://edirc.repec.org/data/izaaade.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.